Topotecan

Rhabdomyosarcoma, Lymphoma, Malignant neoplasm of ovary + 5 more
Treatment
3 FDA approvals
20 Active Studies for Topotecan

What is Topotecan

TopotecanThe Generic name of this drug
Treatment SummaryTopotecan is a medication used to treat ovarian cancer. It works by blocking the activity of an enzyme called DNA topoisomerase type I, which helps cancer cells divide and grow.
Hycamtinis the brand name
image of different drug pills on a surface
Topotecan Overview & Background
Brand Name
Generic Name
First FDA Approval
How many FDA approvals?
Hycamtin
Topotecan
1996
29

Approved as Treatment by the FDA

Topotecan, also known as Hycamtin, is approved by the FDA for 3 uses such as Malignant neoplasm of ovary and refractory, metastatic Ovarian cancer .
Malignant neoplasm of ovary
refractory, metastatic Ovarian cancer
Metastatic Cervical Cancer
Used to treat Metastatic Cervical Cancer in combination with Cisplatin

Effectiveness

How Topotecan Affects PatientsTopotecan is a drug derived from the alkaloid Camptotheca acuminata tree. This anti-tumor drug works by interfering with the growth of cancer cells, blocking an enzyme called DNA topoisomerase I. This enzyme helps with processes like DNA replication, recombination, and repair. Topotecan doesn't affect normal cells as much as cancer cells, but it can still have some other side effects. Unlike irinotecan, topotecan is not a prodrug, which means it will remain in its inactive form at neutral pH.
How Topotecan works in the bodyTopotecan stops cancer cells from reproducing by blocking an enzyme called topoisomerase I. This enzyme helps relieve tension in DNA strands. Topotecan binds to the enzyme-DNA combination and prevents the DNA from being repaired, which causes a double-stranded break in the DNA. Since mammal cells cannot fix these breaks, the cell eventually dies. Topotecan fits between DNA base pairs, preventing them from rejoining, which makes it an uncompetitive inhibitor.

When to interrupt dosage

The prescribed quantity of Topotecan is contingent upon the diagnosed illness, including Malignant neoplasm of ovary, Lymphoma and metastatic Rhabdomyosarcoma. The amount of dosage is determined by the delivery approach noted in the table beneath.
Condition
Dosage
Administration
Lymphoma
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
refractory CNS malignancy
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Malignant Neoplasms
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Malignant neoplasm of ovary
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Rhabdomyosarcoma
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Sarcoma
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Acute Myeloid Leukemia
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral
Neuroblastoma
, 4.0 mg/mL, 1.0 mg/mL, 4.0 mg, 1.0 mg, 0.25 mg, 0.4 mg/mL
Intravenous, , Injection, powder, lyophilized, for solution, Injection, powder, lyophilized, for solution - Intravenous, Injection, powder, for solution, Injection, powder, for solution - Intravenous, Injection, Injection - Intravenous, Powder, for solution - Intravenous, Powder, for solution, Solution, Solution - Intravenous, Injection, solution, concentrate, Injection, solution, concentrate - Intravenous, Oral, Capsule, Capsule - Oral

Warnings

There are 20 known major drug interactions with Topotecan.
Common Topotecan Drug Interactions
Drug Name
Risk Level
Description
2-Methoxyethanol
Major
The risk or severity of adverse effects can be increased when Topotecan is combined with 2-Methoxyethanol.
9-(N-methyl-L-isoleucine)-cyclosporin A
Major
The risk or severity of adverse effects can be increased when Topotecan is combined with 9-(N-methyl-L-isoleucine)-cyclosporin A.
Abatacept
Major
The risk or severity of adverse effects can be increased when Topotecan is combined with Abatacept.
Abemaciclib
Major
The excretion of Abemaciclib can be decreased when combined with Topotecan.
Abetimus
Major
The risk or severity of adverse effects can be increased when Topotecan is combined with Abetimus.
Topotecan Toxicity & Overdose RiskThe main complication of an overdose of this drug would be decreased production of blood cells in the bone marrow.
image of a doctor in a lab doing drug, clinical research

Topotecan Novel Uses: Which Conditions Have a Clinical Trial Featuring Topotecan?

336 active trials are assessing the potential of Topotecan to mitigate Malignant neoplasm of ovary, Malignant Neoplasms and metastatic Rhabdomyosarcoma.
Condition
Clinical Trials
Trial Phases
Acute Myeloid Leukemia
275 Actively Recruiting
Phase 2, Phase 1, Phase 3, Phase 4, Not Applicable, Early Phase 1
Neuroblastoma
0 Actively Recruiting
Malignant neoplasm of ovary
0 Actively Recruiting
Lymphoma
0 Actively Recruiting
Rhabdomyosarcoma
0 Actively Recruiting
refractory CNS malignancy
0 Actively Recruiting
Malignant Neoplasms
0 Actively Recruiting
Sarcoma
1 Actively Recruiting
Phase 2

Topotecan Reviews: What are patients saying about Topotecan?

2Patient Review
4/7/2014
Topotecan for Small Cell Cancer of the Lung
2Patient Review
4/7/2014
Topotecan for Small Cell Cancer of the Lung
image of drug pills surrounding a glass of water symbolizing drug consumption

Patient Q&A Section about topotecan

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are the side effects of topotecan?

"The following are symptoms of poisoning: black, tarry stools; blood in the urine or stools; body aches or pain; chest pain; congestion; difficult or labored breathing; dryness or soreness of the throat; hoarseness."

Answered by AI

How long can you take topotecan?

"Topotecan is typically given on a daily basis for a duration of 3 to 5 days."

Answered by AI

How effective is topotecan?

"In a randomised phase III study, it was found that topotecan was at least as effective as the three-drug regimen of cyclophosphamide 1,000 mg·m-2, doxorubicin 45 mg·m-2 and vincristine 2 mg (CAV)."

Answered by AI

Does topotecan cause hair loss?

"Some effects of the medicine, like hair loss, may not be serious but may still cause some concern. Some unwanted effects may occur even after treatment with topotecan has stopped. This medicine can only be obtained with a prescription from a doctor."

Answered by AI

Clinical Trials for Topotecan

Have you considered Topotecan clinical trials? We made a collection of clinical trials featuring Topotecan, we think they might fit your search criteria.
Have you considered Topotecan clinical trials? We made a collection of clinical trials featuring Topotecan, we think they might fit your search criteria.
Have you considered Topotecan clinical trials? We made a collection of clinical trials featuring Topotecan, we think they might fit your search criteria.
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top